Solventum Corporation (NYSE:SOLV) Receives $85.44 Consensus PT from Analysts

Key Points

• Solventum Corporation (NYSE:SOLV) has received a consensus rating of "Hold" from eleven brokerages, with one sell rating, six hold ratings, and four buy ratings.
• Recent ratings upgrades include Morgan Stanley raising the target price from $80.00 to $103.00 and Wells Fargo increasing it from $79.00 to $82.00.
• Solventum reported $1.69 EPS for the last quarter, exceeding expectations, with revenues of $2.16 billion, a 3.8% increase year-over-year.

Shares of Solventum Corporation (NYSE:SOLV - Get Free Report) have earned an average recommendation of "Hold" from the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $85.4444.

A number of brokerages recently weighed in on SOLV. Morgan Stanley raised Solventum from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Jefferies Financial Group began coverage on Solventum in a research report on Thursday, September 11th. They set a "hold" rating and a $80.00 price objective on the stock. Wells Fargo & Company raised their price objective on Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a research report on Monday, September 15th. Wall Street Zen downgraded Solventum from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, September 9th. Finally, Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st.

Solventum Stock Down 0.8%

Shares of Solventum stock traded down $0.60 during trading on Wednesday, hitting $73.77. 1,491,907 shares of the stock traded hands, compared to its average volume of 1,021,429. The firm has a market cap of $12.79 billion, a P/E ratio of 34.15, a price-to-earnings-growth ratio of 3.03 and a beta of 0.53. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum has a 52-week low of $60.70 and a 52-week high of $85.92. The stock's fifty day simple moving average is $72.98 and its 200 day simple moving average is $72.41.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business's revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

Institutional investors have recently added to or reduced their stakes in the business. Rossby Financial LCC purchased a new position in shares of Solventum in the first quarter worth about $25,000. Strengthening Families & Communities LLC raised its position in Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock valued at $25,000 after acquiring an additional 260 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new position in Solventum during the second quarter valued at approximately $28,000. Barrett & Company Inc. raised its position in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company's stock valued at $30,000 after acquiring an additional 268 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new position in Solventum during the second quarter valued at approximately $31,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.